LIFD LFTD PARTNERS INC.
Pharmaceutical Preparations · OTC · SEC CIK 1391135 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-15.9%
TTM net income YoY-53,461.9%
TTM EPS YoY—
Revenue 3-yr CAGR-14.3%
Net income 3-yr CAGR—
Margins
Gross margin8.3%
Operating margin-27.9%
Net margin-108.9%
FCF margin2.1%
EBITDA margin-26.8%
Returns
ROE-164.2%
ROA-127.1%
ROIC (approx.)-38.3%
Asset turnover1.17x
Leverage & solvency
Liabilities / assets55.7%
Debt / equity0.00x
Current ratio1.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.02x
Accruals ratio-130.2%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $36.92M | $37.33M | $51.61M | $57.42M | $31.66M |
| Cost of revenue | $24.30M | $24.57M | $31.91M | $36.42M | $15.72M |
| Gross profit | $12.62M | $12.75M | $19.70M | $20.99M | $15.94M |
| R&D expense | — | — | $19,800 | $19,800 | — |
| Operating income | $913,208 | -$773,464 | $2.41M | $9.81M | $7.78M |
| Interest expense | — | — | $110,517 | $120,197 | $142,427 |
| Pretax income | -$24.43M | -$2.38M | $2.76M | $9.99M | $7.17M |
| Income tax | $432,824 | -$524,425 | $598,065 | -$2.80M | $1.37M |
| Net income | -$24.86M | -$1.86M | $2.16M | $7.20M | $5.80M |
| EBITDA | $1.47M | -$252,833 | $2.84M | $10.00M | $7.87M |
| EPS (basic) | -1.68 | -0.13 | 0.15 | 0.51 | 0.50 |
| EPS (diluted) | -1.68 | -0.13 | 0.13 | 0.45 | 0.43 |
| Weighted avg. shares (diluted) | 14.82M | 14.80M | 16.44M | 15.86M | 13.36M |
| Banking | |||||
| Deposits | $1.00M | $1.00M | — | — | — |
| Balance sheet | |||||
| Cash & equivalents | $1.77M | $3.15M | $5.36M | $3.53M | $1.60M |
| Receivables | $2.53M | $2.66M | $3.59M | $2.41M | $3.46M |
| Inventory | $10.96M | $9.32M | $10.17M | $6.02M | $3.81M |
| Current assets | $15.69M | $17.23M | $21.67M | $13.85M | $13.15M |
| PP&E, net | $2.27M | $2.70M | $3.00M | $1.02M | $433,213 |
| Goodwill | $0 | $23.09M | $23.09M | $22.29M | $22.29M |
| Intangibles | $0 | — | — | $0 | $1,386 |
| Total assets | $19.27M | $47.62M | $51.35M | $41.13M | $39.42M |
| Current liabilities | $5.16M | $6.39M | $8.69M | $6.21M | $11.91M |
| Total liabilities | $6.64M | $10.12M | $12.53M | $6.59M | $11.96M |
| Shareholders' equity | $12.63M | $37.50M | $38.82M | $34.54M | $27.46M |
| Shares outstanding | 14.82M | 14.82M | 14.81M | 14.10M | 14.03M |
| Cash flow statement | |||||
| Operating cash flow | $1.32M | -$960,067 | $638,925 | $3.04M | $5.62M |
| Capital expenditure | $121,639 | $313,763 | $789,662 | $916,119 | $368,223 |
| Free cash flow | $1.20M | -$1.27M | -$150,737 | $2.12M | $5.25M |
| Investing cash flow | -$121,639 | -$479,574 | -$2.52M | -$916,119 | -$446,655 |
| Financing cash flow | -$2.58M | -$770,951 | $3.70M | -$193,416 | -$4.01M |
| Depreciation & amortization | $552,877 | $520,631 | $425,614 | $191,541 | $90,146 |
| Stock-based compensation | — | — | — | $0 | $0 |
| Dividends paid | — | — | — | — | $11,844 |
| Share buybacks | $0 | $240,240 | $0 | $150,000 | $34,200 |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.